`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`
`MYLAN PHARMACEUTICALS INC.,
`
`Petitioner,
`
`v.
`
`BAUSCH HEALTH IRELAND LIMITED,
`
`Patent Owner.
`
`__________________
`
`Case IPR2022-00722
`U.S. Patent No. 7,041,786
`__________________
`
`PATENT OWNER’S UPDATED EXHIBIT LIST
`
`
`
`
`
`
`
`
`
`
`
`
`Case No. IPR2022-00722
`U.S. Patent No. 7,041,786
`
`Pursuant to 37 C.F.R. § 42.63(e), Patent Owner Bausch Health Ireland
`
`Limited hereby submits a current listing of Patent Owner Exhibits. Exhibits 2023-
`
`2046, 2048-2062, and 2064-2065 were filed on P-TACTS and served via email to
`
`counsel of record for the Petitioner.
`
`EXHIB
`IT
`
`2001
`
`DESCRIPTION
`
`Bausch Health Ireland Ltd. et al. v. MSN Lab’ys Private Ltd. et al., Civil
`Action No. 2:21-cv-10057 (D.N.J.), ECF No. 51, Amended Scheduling
`Order, Entered January 5, 2022.
`
`2002
`
`Bausch Health Ireland Ltd. et al. v. Mylan Pharms. Inc, Civil Action
`No. 1:22-cv-00020 (N.D. W. Va.), ECF No. 98-1, Parties Proposed
`Scheduling Order Checklists, Submitted May 16, 2022.
`2003 MSN Defendants’ First Set of Requests For Production to Plaintiffs
`(Nos. 1-50), Served on January 11, 2022.
`2004 Case Docket of Bausch Health Ireland Ltd. et al. v. MSN Lab’ys Private
`Ltd. et al., Civil Action No. 2:21-cv-10057 (D.N.J.)
`2005 Mylan Defendants’ First Set of Requests For Production to Plaintiffs
`(Nos. 1-132), Served on May 19, 2022.
`
`2006
`
`2007
`
`2008
`
`MSN’s Notice of Paragraph IV Certification Re: MSN’s Plecanatide
`Tablets, 3mg, U.S. Patent Nos. 7,041,786; 9,610,321; 9,616,097;
`9,919,024; 9,925,231; 10,011,637, Dated March 15, 2021 (Excerpt).
`
`Mylan’s Notice of Paragraph IV Certification Re: Mylan’s Plecanatide
`Tablets, 3mg, U.S. Patent Nos. 7,041,786; 9,610,321; 9,616,097;
`9,919,024; 9,925,231; 10,011,637, Dated March 18, 2021.
`
`Hidaka et al., “In Vitro Disulfide-Coupled Folding of Guanylyl Cyclase-
`Activating Peptide and Its Precursor Protein,” Biochemistry, Vol. 37,
`No. 23, 8498-8507 (1998).
`
`2
`
`
`
`
`Case No. IPR2022-00722
`U.S. Patent No. 7,041,786
`
`
`2009
`
`2010
`
`2011
`
`2012
`
`Hidaka et al., “Dual Function of the Propeptide of Prouroguanylin in the
`Folding of the Mature Peptide,” The Journal of Biological Chemistry,
`Vol. 275, No. 33, 25155-25162 (2000).
`
`Marx et al., “One peptide, two topologies: structure and interconversion
`dynamics of human uroguanylin isomers,” J. Peptide Res. 52, 229-240
`(1998).
`
`isomers of human uroguanylin:
`Chino et al., “Topological
`interconversion between biologically active and inactive isomers,”
`FEBS Letters, 421, 27-31 (1998).
`
`Hamra et al., “Uroguanylin: Structure and activity of a second
`endogenous peptide that stimulates intestinal guanylate cyclase,” Proc.
`Natl. Acad. Sci. USA, Vol. 90, 10464-10468 (1993).
`
`2013
`
`Ironwood Press Release, “Ironwood Pharmaceuticals Promotes Dr.
`Mark Currie to Senior Vice President, Chief Scientific Officer, and
`President of R&D,” Dated February 11, 2013.
`2014 U.S. Patent No. 7,371,727, titled “Methods and Compositions for the
`Treatment of Gastrointestinal Disorders.”
`2015 U.S. Patent No. 7,704,947, titled “Methods and Compositions for the
`Treatment of Gastrointestinal Disorders.”
`2016 U.S. Patent No. 7,745,409, titled “Methods and Compositions for the
`Treatment of Gastrointestinal Disorders.”
`2017 U.S. Patent No. 8,080,526 titled “Methods and Compositions for the
`Treatment of Gastrointestinal Disorders.”
`2018 U.S. Patent No. 8,110,553, titled “Methods and Compositions for the
`Treatment of Gastrointestinal Disorders.”
`
`2019
`
`targeting guanylate cyclase-C:
`Brancale et al, “Therapeutically
`computational modeling of plecanatide, a uroguanylin analog,” Pharma
`Res Per, Vol. 5, Iss. 2, 1-10 (2017).
`
`3
`
`
`
`
`Case No. IPR2022-00722
`U.S. Patent No. 7,041,786
`
`
`2020
`
`2021
`
`Klodt et al., “Synthesis, biological activity and isomerism of guanylate
`cyclase C-activating peptides guanylin and uroguanylin,” J. Peptide
`Res. 50, 222-230 (1997).
`
`International Publication Number WO 01/25266, titled “Uroguanylin as
`an Intestinal Cancer Inhibiting Agent.”
`
`A file history of EP1379224, titled “Guanylate Cyclase Receptor
`2022
`Agonists
`for
`the Treatment of Tissue
`Inflammation
`and
`(Served
`Carcinogenesis.”
`Only)
`2023 CONFIDENTIAL Declaration of Kunwar Shailubhai. (Under Seal and
`Public versions)
`2024 CONFIDENTIAL Declaration of Stephen G. Davies. (Under Seal and
`Public versions)
`2025 CONFIDENTIAL Declaration of Scott A. Waldman. (Under Seal and
`Public versions)
`2026 Transcript of November 1, 2022 Deposition of Blake R. Peterson.
`
`2027 CONFIDENTIAL Shailubhai, K., “SP-304: Stimulation of Intracellular
`cGMP Synthesis
`in T84 Cells”, Study No. SP-PH-001,
`TRUL00018203-24 (2008). (Under Seal and Public versions)
`2028 CONFIDENTIAL Shailubhai, K., “Studies on SP-304 Thermostability,
`pH Dependency and Topoisomeric Stability”, Study No. SP-PH-004,
`TRUL00018260-77 (2008). (Under Seal and Public versions)
`2029 Curriculum Vitae of Stephen G. Davies.
`
`2030 Curriculum Vitae of Scott A. Waldman.
`
`2031
`
`“FDA approves Trulance for Chronic Idiopathic Constipation”, FDA
`News Release
`(January 19, 2017), https://www.fda.gov/news-
`events/press-announcements/fda-approves-trulance-chronic-idiopathic-
`constipation.
`
`4
`
`
`
`
`Case No. IPR2022-00722
`U.S. Patent No. 7,041,786
`
`
`2032 Dressman, et al., “Upper Gastrointestinal (GI) pH in Young, Healthy
`Men and Women”, Pharmaceutical Research, Vol. 7, No. 7, 756-61
`(1990).
`
`2033 Nugent, et al., “Intestinal luminal pH in inflammatory bowel disease:
`possible
`determinants
`and
`implications
`for
`therapy with
`aminosalicylates and other drugs”, Gut, Vol. 48, No. 4, 571-77 (2001).
`
`2034 Rudin, “Chapter 4 - Effects of Polymer Isomerism on Conformational
`Changes”, Elements of Polymer Science & Engineering (1999), PP. 121-
`153.
`
`2035
`
`2036
`
`Jonson, et al., “A critical view on conservative mutations”, Protein
`Engineering, Vol. 14, No. 6, 397-402 (2001).
`
`Fiser, et al., “Conservation of amino acids in multiple alignments:
`aspartic acid has unexpected conservation”, FEBS Letters, 397, 225-229
`(1996).
`
`2037 Garcia et al., “Processing and Characterization of Human Proguanylin
`Expressed in Escherichia coli”, Journal of Biological Chemistry, Vol.
`268, No. 30, 22397-22401 (1993).
`
`2038 Takada et al., “Alternation of a Single Amino Acid in Peroxisome
`Proliferator-Activated Receptor-α (PPARα) Generates a PPARδ
`Phenotype”, Molecular Endocrinology, Vol. 14, No. 5, 733-740 (2000).
`
`2039
`
`Sood, et al., “Peroral Route: An Opportunity for Protein and Peptide
`Drug Deliveryϯ”, Chem. Rev., Vol. 101, No. 11, 3275-3303 (2001).
`
`2040 Letter from Michael Pennington, Ph.D. to Dr. Kunwar Shailubhai
`(March 31, 2004).
`
`2041 Grossman, “Characterization of a Pure Gastrin”, Gastrin: Proceedings
`of a Conference Held in September 1964, University of California Press,
`Los Angeles (1966), Pp. 26-47.
`
`2042 Barrett et al., “Chapter 6: Synthesis of Amino Acids”, Amino Acids and
`Peptides, Cambridge University Press (1998), Pp. 120-129.
`
`5
`
`
`
`
`Case No. IPR2022-00722
`U.S. Patent No. 7,041,786
`
`
`2043
`
`Jeng et al., “Direct Measurement of the Aspartic Acid 26 pKa for
`Reduced Escherichia coli Thioredoxin by 13C NMR”, Biochemistry,
`Vol. 35, No. 1, 1-6 (1996).
`
`2044 Nguyen et al., “X-ray and thermodynamic studies of staphylococcal
`nuclease variants I92E and I92K: insights into polarity of the protein
`interior”, Journal of Molecular Biology, Vol. 341, No. 2, 565-74 (2004).
`
`2045 Harms et al., “The pKa values of acidic and basic residues buried at the
`same internal location in a protein are governed by different factors”,
`Journal of Molecular Biology, Vol. 389, No. 1, 34-47 (2009).
`
`2046 Liu et al., “In Vivo Imaging of Human Colorectal Cancer Using
`Radiolabeled Analogs of
`the Uroguanylin Peptide Hormone”,
`Anticancer Research, Vol. 29, 3777-3784 (2009).
`2047 Reserved.
`
`2048 Borgaonkar et al., “Quality of life measurement in gastrointestinal and
`liver disorders”, Gut, Vol. 47, Iss. 3, 444-54 (2000).
`
`2049
`
`Francis et al., “The irritable bowel syndrome”, Postgraduate Medical
`Journal, Vol. 73, 1-7 (1997).
`
`2050 Wald, “Chapter 41: Approach to the Patient with Constipation”,
`Textbook of Gastroenterology, (Tadataka Yamada ed., 3rd Ed., Vol. 1,
`Lippincott Williams & Wilkins 1999).
`
`2051 Thompson et al., “Functional bowel disorders and functional abdominal
`pain”, Gut, Vol. 45, Suppl. II, II43-7 (1999).
`
`2052 Collins et al., “The putative role of inflammation in the irritable bowel
`syndrome”, Gut, Vol. 49, Iss. 6, 743-5 (2001).
`
`2053 Camilleri et al., “Visceral hypersensitivity: facts, speculations, and
`challenges”, Gut, Vol. 48, Iss. 1, 125-31 (2001).
`
`2054
`
`Suares et al., “Prevalence of, and risk factors for, chronic idiopathic
`constipation in the community: systematic review and meta-analysis”,
`
`6
`
`
`
`
`The American Journal of Gastroenterology, Vol. 106, No. 9, 1582-91
`(2011).
`
`Case No. IPR2022-00722
`U.S. Patent No. 7,041,786
`
`
`2055
`
`Sandler et al., “Demographic and dietary determinants of constipation
`in the US population”, The American Journal of Public Health, Vol. 80,
`No.2, 185-9 (1990).
`
`2056
`
`Faigel, “A clinical approach to constipation”, Clinical Cornerstone, Vol.
`4, Iss. 4, 11-18 (2002).
`
`2057 Zalewski, “Cisapride Withdrawal Requires Alternative Therapy”,
`Cleveland Clinic, Center for Continuing Education, Pharmacotherapy
`Update,
`Vol.
`3,
`No.
`2
`(2000),
`https://www.clevelandclinicmeded.com/medicalpubs/pharmacy/mayju
`ne2000/cisapride.htm.
`
`2058 Bharucha et al., “Mechanisms, Evaluation, and Management of Chronic
`Constipation”, Gastroenterology, Vol. 158, No. 5, 1232-1249 (2020).
`
`2059 Chey et al., “Randomized Trial of 2 Delayed-Release Formulations of
`Linaclotide
`in Patients With Irritable Bowel Syndrome With
`Constipation”, The American Journal of Gastroenterology, Vol. 116,
`Iss. 2, 354-361 (2021).
`
`2060 Carpick et al., “The Escherichia coli heat-stable enterotoxin is a long-
`lived superagonist of guanylin”, Infection and Immunity, Vol. 61, No.
`11, 4710-5 (1993).
`
`2061 Lucas et al., “Guanylyl cyclases and signaling by cyclic GMP”,
`Pharmacological Reviews, Vol. 52, No. 3, 375-413 (2000).
`
`2062 Bełtowski, “Guanylin and related peptides”, Journal of Physiology and
`Pharmacology, Vol. 52, No. 3, 351-75 (2001).
`
`2063 Reserved.
`
`2064 Trulance® Label (October 2020).
`
`2065 Kita et al., “Characterization of human uroguanylin: a member of the
`guanylin peptide family”, The American Journal of Physiology, Vol.
`266, Iss. 2, F342-8 (1994).
`
`7
`
`
`
`
`Case No. IPR2022-00722
`U.S. Patent No. 7,041,786
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`
`
`Date: December 14, 2022
`
`
`/Justin J. Hasford/
`By:
`Justin J. Hasford, Reg. No. 62,180
`Lead Counsel
`Bryan C. Diner, Reg. No. 32,409
`Back-up Counsel
`Joshua L. Goldberg, Reg. No. 59,369
`Back-up Counsel
`Kassandra M. Officer Reg. No. 74,083
`Back-up Counsel
`Lauren J. Robinson Reg. No. 74,100
`Back-up Counsel
`Caitlin E. O’Connell, Reg. No. 73,934
`Back-up Counsel
`Kyu Yun Kim, Reg. No. 72,783
`Back-up Counsel
`
`FINNEGAN, HENDERSON, FARABOW,
` GARRETT & DUNNER, L.L.P.
`901 New York Ave. NW
`Washington, DC 20001-4413
`(202) 408-4000
`
`Counsel for the Patent Owner
`
`8
`
`
`
`
`Case No. IPR2022-00722
`U.S. Patent No. 7,041,786
`
`
`CERTIFICATE OF SERVICE
`
`
`
`The undersigned hereby certifies that a copy of the foregoing Patent Owner’s
`
`Updated Exhibit List and Exhibits 2023-2046, 2048-2062, and 2064-2065 served
`
`electronically via email on December 14, 2022, to counsel of record for the Petitioner
`
`at the following:
`
`Jad A. Mills
`Wilson Sonsini Goodrich & Rosati PC
`701 Fifth Avenue, Suite 5100
`Seattle, WA 98104-7036
`jmills@wsgr.com
`4863-5899-2145@mail.vault.netdocuments.com
`
`Richard Torczon
`Wilson Sonsini Goodrich & Rosati PC
`1700 K Street N.W., 5th Floor
`Washington, DC 20006
`rtorczon@wsgr.com
`
`Nicole W. Stafford
`Dennis D. Gregory
`Wilson Sonsini Goodrich & Rosati PC
`900 South Capital of Texas Highway, Las Cimas IV, Fifth Floor
`Austin, TX 78746-5546
`nstafford@wsgr.com
`dgregory@wsgr.com
`
`
`
`
`
`
`
`
`
`
`/Lisa C. Hines/
`Lisa C. Hines
`Senior Litigation Legal Assistant
`FINNEGAN, HENDERSON, FARABOW,
` GARRETT & DUNNER LLP
`
`
`
`
`
`
`
`
`Dated: December 14, 2022
`
`
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
